Allergan, Inc. announced operating results for the quarter ended June 30, 2014 and announced a restructuring that will eliminate 1500 jobs.
Aptuit Names Executive VP, Business Development & Marketing; Enhances Sterile Drug Product CapabilitiesJuly 16, 2014 11:33 am | News | Comments
Aptuit LLC has appointed Paul D. Overton, Ph.D., as Executive Vice President, Business...
Bayer today announced the appointment of Malini Moorthy as Head of the Litigation Department in...
Merck KGaA’s biopharmaceutical division today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.
Chinese authorities formally indicted two corporate investigators, an American and Briton, for allegedly illegally obtaining and selling private information, state media reported Monday. Prosecutors in Shanghai filed charges against British investigator Peter Humphrey and his wife Yingzeng Yu, a U.S. citizen, at the city's No. 1 Intermediate People's Court, the official Xinhua News Agency said.
ScinoPharm announced that after 17 years of dedicated service, its co-founder and President & CEO Dr. Jo Shen is retiring at the end of July 2014 and will be succeeded by Dr. Yung-Fa (Fred) Chen, currently Sr. Vice President of R&D and Chief Technology Officer, effective August 1, 2014.
Vertex Pharmaceuticals Incorporated today announced that Peter Mueller, Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company.
Arena Pharmaceuticals, reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ by 50% to approximately 600.
Ortho-Clinical Diagnostics Announces Executive Leadership Additions as It Becomes an Independent, Stand-Alone CompanyJuly 8, 2014 8:58 am | News | Comments
Ortho-Clinical Diagnostics, Inc. unveiled its newly expanded executive leadership team following the acquisition of the company by The Carlyle Group from Johnson & Johnson.
AAIPharma Services Corp., a global provider of pharmaceutical analytical testing, product development and manufacturing services, and Cambridge Major Laboratories, Inc., a provider pharmaceutical API development and manufacturingservices, announced the appointment of Stephan Kutzer, Ph.D. as Chief Executive Officer (CEO), effective August 1, 2014.
Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.
Alexza Pharmaceuticals has announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will have primary responsibility for leading and directing all regulatory affairs and global pharmacovigilence activities.
Seeking to turn around a troubled agency, President Barack Obama will nominate former Procter & Gamble executive Robert McDonald to lead a Veterans Affairs department gripped by reports of treatment delays and cover-ups.
Tris Pharma, a specialty pharmaceutical company focused on developing innovative technology-based products announced two key additions to its' executive team: Sally A. Berry, MD, PhD will join as Chief Medical Officer and Norma Cappetti will join as Vice President of Regulatory Affairs.
As a result of an in-depth review of the company’s research & development portfolio, InVivo Therapeutics has announced that the company is realigning resources behind its novel Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells program for spinal cord injury (SCI).
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Barry Lederman to the position of Vice President and Chief Financial Officer (CFO). In this role, Mr.Lederman will have full oversight and responsibility for leading Eisai's financial operations in the Americas Region.
Actavis and Forest Labs today announced that C. David Nicholson, PhD will be appointed Senior Vice President, Actavis Global Brands R&D following the close of Actavis' planned acquisition of Forest. In this role, Dr. Nicholson will lead the global teams focused on developing Actavis' significantly expanded branded R&D portfolio, as well as defining long-term product development strategies and collaborations.
Noven Pharmaceuticals announced the appointment of Krista Roberts as the company’s new Vice President of Operations. In this role, Roberts will be responsible for all Noven manufacturing and related operations.
Bioanalytical Systems, Inc. (BASi) today announced the appointment of Jeffrey Potrzebowski as Chief Financial Officer and James S. Bourdage, Ph.D., as Vice President Bioanalytical Operations.
In line with his own wishes, the contract of Dr. Marijn Dekkers will be extended by just two years on expiration of the initial five-year period. Dekkers cited family reasons for extending his contract only until the end of 2016.
Teva Pharmaceutical Industries has announced a new organizational structure and related executive positions, designed to achieve seamless global integration, focus and effectiveness across the company. The changes will become effective July 1st.
Pfizer announced that Morris J. Birnbaum, M.D., Ph.D., has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research. He will report directly to Rod MacKenzie, Ph.D., Group Senior Vice President and Head of PharmaTherapeutics Research & Development, and will be based in a key Pfizer R&D hub in Cambridge, MA.
Last year was the fourth straight that CEO compensation rose following a decline during the Great Recession. The median CEO pay package climbed more than 50 percent over that stretch. A chief executive now makes about 257 times the average worker's salary.
Hikma will be acquiring Bedford Laboratories' assets, including a large product portfolio, intellectual property rights, contracts for products marketed under license, raw material inventories, a strong research and development and business development pipeline, and a number of employees across key business functions.
PAREXEL International, a global biopharmaceutical services organization, today named Dr. Sy Pretorius its Chief Scientific Officer. Dr. Pretorius currently serves as the company's Corporate Vice President and Worldwide Head of Early Phase, and will continue in that capacity in addition to assuming his expanded responsibilities.
Here are the 10 highest-paid CEOs of 2013, as calculated by The Associated Press and Equilar, an executive pay research firm.
Celgene Corporation today announced several organizational changes that will go into effect on August 1, 2014.
Purdue Pharma today announced that Saeed Motahari has joined the company as Senior Vice President and Chief Commercial Officer.
- Page 1